PF-Atlas › Clinical Trials › NCT04268823
Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease
QBW251 · Phase 2
Registry ID
NCT04268823
Phase
Phase 2
Status
Terminated
Drug / intervention
QBW251
Sponsor
Novartis Pharmaceuticals
Start
2020-09-10
Enrollment
54
Locations
12
About this trial
The purpose of this study was to determine whether potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD would be efficacious with regards to reducing lung and systemic inflammation and bacterial colonization as potential drivers of airway obstruction, airway destruction, remodeling and exacerbations. Furthermore, this study provided supportive data to investigate the relationship of COPD phenotype and the response in small airway structure, function, mucus load and spirometry indices as well as in improvement of overall COPD symptoms and quality of life.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04268823 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.